20 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 20 of 20 clinical reviews.
Is metformin effective for cancer prevention? We review the clinical evidence, dosing protocols, and limitations of off-label metformin use for reducing cancer risk.
Metformin is FDA-approved for type 2 diabetes, but observational data suggest it may reduce cancer incidence. Here is what the trials show, what remains unproven, and how to monitor patients using metformin off-label for cancer risk reduction.
A analysis of metformin's off-label use for cancer prevention, including trial data, proposed mechanisms, risk-benefit tradeoffs, and who might benefit most.
A clinical evidence summary of metformin's off-label use for cancer prevention, including key trials, biological mechanisms, and current guideline positions.
Off-label metformin, not pioglitazone, is guideline-backed for PCOS insulin resistance, restoring ovulation in 50-70% of anovulatory women.
Is metformin a longevity drug? We review the biology, clinical trial data from TAME and beyond, GRADE evidence levels, off-label status, and what prescribers and patients need to know before considering metformin for aging.
Metformin is prescribed off-label for longevity based on observational data and preclinical evidence. Here is what the clinical trials show, how physicians dose it, and what TAME will tell us.
A clinical review of metformin's off-label use for longevity, including trial data, AMPK mechanisms, side effects, and who may or may not benefit from anti-aging metformin therapy.
A clinical deep-dive into whether metformin works for non-alcoholic fatty liver disease (NAFLD): current evidence grade, off-label dosing protocols, and what the guidelines actually say.
Metformin is sometimes prescribed off-label for nonalcoholic fatty liver disease (NAFLD). This evidence summary reviews the clinical trial data, guideline positions, and practical considerations for metformin use in NAFLD.
Metformin is widely prescribed off-label for NAFLD, but clinical trials show limited histological benefit. Learn the real evidence, risks, tradeoffs, and better-studied alternatives.
Metformin is sometimes used off-label for nonalcoholic fatty liver disease (NAFLD). Learn what the evidence shows, how monitoring works, and what guidelines recommend.
Metformin is widely prescribed off-label for polycystic ovary syndrome (PCOS). Learn the dosing protocol, clinical evidence from key trials, side effects, and how it compares to other PCOS treatments.
Metformin is used off-label for PCOS to improve insulin sensitivity, restore ovulation, and lower androgen levels. Learn what the clinical trials show, who benefits most, and what risks to weigh before starting.
A clinical evidence summary of off-label metformin use for weight maintenance, including trial data from the DPP/DPPOS, dosing guidance, and how it compares to newer GLP-1 therapies.
Metformin is FDA-approved for type 2 diabetes, but clinicians increasingly prescribe it off-label for weight maintenance. This evidence-based guide covers the clinical trial data, GRADE evidence levels, risks, and who may benefit most.
Metformin is used off-label for weight maintenance after initial weight loss. Review the clinical trial evidence, required lab monitoring, dosing protocols, and safety considerations for long-term use.
Metformin is FDA-approved for type 2 diabetes but is used off-label for weight maintenance. Learn what the clinical evidence shows, who may benefit, and how dosing is typically structured.
Metformin isn't FDA-approved for PCOS but is used off-label to improve insulin sensitivity and ovulation. Learn required monitoring and dosing basics.
TAME trial is still ongoing, no FDA approval yet. See required labs for off-label metformin use: eGFR, B12, lactate, liver panel and glucose intervals.